GlassScriptPhysician profile
Aarati B Malliah
NPI 1962613125
$5,945.29
in general payments reported to CMS, 2019-2025
32 companies · $991 in 2025
The $991 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $663 · 2020: $107 · 2021: $526 · 2022: $1,149 · 2023: $1,249 · 2024: $1,259 · 2025: $991.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,480 · Education: $20.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,479.62 |
| Education | $20.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,656.37 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $974.64 | 2019-2025 | Xifaxan, Trulance, Plenvu |
| Takeda Pharmaceuticals U.S.A., INC. | $570.70 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Celgene Corporation | $461.90 | 2021-2024 | Zeposia |
| Janssen Biotech, INC. | $409.34 | 2019-2025 | Tremfya, Stelara, Simponi |
| Lilly USA, LLC | $162.11 | 2023-2025 | Omvoh |
| Gilead Sciences, INC. | $148.18 | 2019-2025 | |
| Ferring Pharmaceuticals INC. | $142.62 | 2019-2023 | Rebyota, Cimzia |
| Regeneron Healthcare Solutions, INC. | $122.49 | 2022-2025 | Dupixent |
| Nestle Healthcare Nutrition INC. | $122.33 | 2021-2023 | |
| Phathom Pharmaceuticals, INC. | $106.42 | 2024-2025 | Voquezna |
| Madrigal Pharmaceuticals | $102.03 | 2024-2025 | Rezdiffra, Resmetirom |
| Pfizer INC. | $96.16 | 2019-2025 | |
| Aimmune Therapeutics, INC. | $94.35 | 2024-2025 | Zenpep |
| Ardelyx, INC. | $87.86 | 2023-2025 | Ibsrela |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $85.96 | 2019-2024 | Dificid |
| Ipsen Biopharmaceuticals, INC | $80.17 | 2024-2025 | Iqirvo, Bylvay |
| Qol Medical, LLC | $68.23 | 2022-2025 | Sucraid, Sucraid |
| Laborie Medical Technologies Corp. | $64.54 | 2023 | |
| Ironwood Pharmaceuticals, INC | $62.31 | 2019-2025 | Linzess |
| Genzyme Corporation | $59.26 | 2022-2024 | |
| Daiichi Sankyo INC. | $47.33 | 2019-2024 | Injectafer |
| Shire North American Group INC | $32.45 | 2019 | |
| Romark Laboratories, Lc | $29.28 | 2019-2020 | |
| Redhill Biopharma INC. | $27.69 | 2021 | |
| Evoke Pharma, INC. | $27.64 | 2023 | Gimoti |
| Fujifilm Healthcare Americas Corporation | $27.51 | 2021 | |
| Celltrion USA INC. | $18.89 | 2025 | Vegzelma |
| Organon LLC | $15.05 | 2023 | |
| Vivus LLC | $14.93 | 2019 | |
| Intercept Pharmaceuticals, INC. | $14.80 | 2023 | Ocaliva |
| Allergan, INC. | $11.75 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Aarati Malliah listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.